Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReALiSe: ARGX-119 in Amyotrophic Lateral Sclerosis
NCT06441682Phase 2Terminated
- Sponsor
- argenx
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of adimanebart in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by argenx. Primary endpoint: Adverse Events at 96 weeks. Started Oct 2024; status: terminated.
02
Drugs
adimanebart
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06441682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441682.